Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.54 |
| ▸ | NPC1 | O15118 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | PHGDH | O43175 | 1/20 | 0.46 |
| ▸ | MGLL | Q99685 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 5/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10242473 | 0.86 | — | — | |
| SCHEMBL20331851 | 0.86 | — | — | |
| SCHEMBL13841231 | 0.86 | — | — | |
| SCHEMBL14009909 | 0.81 | ALDH1A1 (0.50) | ALDH1A1NPC1MEN1KMT2AACHE | |
| Tert-Butyl Formate SCHEMBL27639043 | 0.80 | TDP1 (0.42) | ALDH1A1NPC1MEN1KMT2AACHE | |
| SCHEMBL25446918 | 0.79 | ALDH1A1 (0.58) | ALDH1A1NPC1MEN1KMT2AACHE | |
| SCHEMBL2566319 | 0.79 | KDM1A (0.37) | ALDH1A1NPC1MEN1KMT2AGAA | |
| SCHEMBL4743328 | 0.79 | KDM1A (0.37) | ALDH1A1GAAHTT | |
| SCHEMBL2606432 | 0.79 | ALDH1A1 (0.40) | ALDH1A1NPC1MEN1KMT2AACHE | |
| SCHEMBL23581929 | 0.78 | ALDH1A1 (0.50) | ALDH1A1NPC1MEN1KMT2AACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 170 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115003655-B | Cycloalkyl urea derivatives | 住友制药株式会社 | 2025-03-21 | — | — | CN | claimed |
| US-20230293517-A1 | ANTAGONIST COMPOUNDS | JANSSEN PHARMCEUTICA NV (BE) | 2023-09-21 | — | — | US | claimed |
| US-20230088694-A1 | CYCLOALKYLUREA DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2023-03-23 | — | — | US | claimed |
| US-20220306588-A1 | BEZIMIDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2022-09-29 | — | — | US | claimed |
| US-11453647-B2 | Benzimidazole derivatives as adenosine receptor antagonists | MERCK PATENT GMBH (DE) | 2022-09-27 | — | — | US | claimed |
| CN-115003655-A | Cycloalkyl urea derivatives | 住友制药株式会社 | 2022-09-02 | — | — | CN | claimed |
| EP-3672952-A1 | BEZIMIDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | Merck Patent GmbH (DE) | 2020-07-01 | — | — | EP | claimed |
| WO-2019038215-A1 | BEZIMIDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2019-02-28 | — | — | WO | claimed |
| EP-2763990-B1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2017-02-22 | — | — | EP | claimed |
| EP-2760862-B1 | 6-(4-HYDROXY-PHENYL)-3-ALKYL-1H-PYRAZOLO[3,4-B]PYRIDINE-4-CARBOXYLIC ACID AMIDE DERIVATIVES AS KINASE INHIBITORS | SANOFI SA (FR) | 2015-10-21 | — | — | EP | claimed |
| EP-2534132-A1 | SUBSTITUTED PYRROLIDINE-2-CARBOXAMIDES | F. Hoffmann-La Roche AG (CH) | 2012-12-19 | — | — | EP | claimed |
| US-20100152190-A1 | Substituted Pyrrolidine-2-Carboxamides | F. HOFFMANN-LA ROCHE AG (CH) | 2010-06-17 | — | — | US | claimed |
| EP-1946777-A1 | Substituted pyrazoline for preventing weight gain | Laboratorios del Dr. Esteve S.A. (ES) | 2008-07-23 | — | — | EP | claimed |
| EP-1946778-A1 | Active substance combination for the treatment of diabetes | Laboratorios del Dr. Esteve S.A. (ES) | 2008-07-23 | — | — | EP | claimed |
| EP-1917247-A1 | 4,5-DIHYDR0-1H-PYRAZOLE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | Laboratorios del Dr. Esteve S.A. (ES) | 2008-05-07 | — | — | EP | claimed |
| US-20070073056-A1 | 4-Substituted Pyrazoline Compounds, their Preparation and Use as Medicaments | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-03-29 | — | — | US | claimed |
| WO-2007009689-A1 | 4,5-DIHYDR0-1H-PYRAZOLE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR.ESTEVE, S.A. (ES) | 2007-01-25 | — | — | WO | claimed |
| WO-2007009690-A1 | HETEROCYCLYL-SUBSTITUTED PYRAZOLINE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A (ES) | 2007-01-25 | — | — | WO | claimed |
| EP-1743894-A1 | Heterocyclyl-substituted pyrazoline compounds, their preparation and use as medicaments | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-01-17 | — | — | EP | claimed |
| EP-1743890-A1 | 4,5-Dihydro-1H-pyrazole derivatives, their preparation and use as medicaments | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-01-17 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070073056-A1 | 4-Substituted Pyrazoline Compounds, their Preparation and Use as Medicaments | P2RX4, PIR, P2RY4 | ALDH1A1 1573/4885NPC1 1095/4885MEN1 1294/4885 |
| US-20230293517-A1 | ANTAGONIST COMPOUNDS | ADORA2B, ADORA2A, ADORA1 | ALDH1A1 639/4885NPC1 1922/4885MEN1 1375/4885 |
| US-20220306588-A1 | BEZIMIDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | ADORA1, ADORA2A, ADORA3 | ALDH1A1 1065/4885NPC1 1078/4885MEN1 3467/4885 |
| US-20100152190-A1 | Substituted Pyrrolidine-2-Carboxamides | ARG2, CCNY, PYCR1 | ALDH1A1 2027/4885NPC1 3196/4885MEN1 2579/4885 |
| US-11453647-B2 | Benzimidazole derivatives as adenosine receptor antagonists | ADORA1, ADORA2A, ADORA3 | ALDH1A1 617/4885NPC1 1208/4885MEN1 3945/4885 |
| US-20230088694-A1 | CYCLOALKYLUREA DERIVATIVE | HCRTR2, HCRTR1, CRHR2 | ALDH1A1 2531/4885NPC1 469/4885MEN1 3411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.